Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310231 | 1.00 | CYP3A4 (0.35) | CYP3A4TDP1TAAR1SLC6A2MAOA | |
| SCHEMBL613867 | 1.00 | CYP3A4 (0.35) | CYP3A4TDP1TAAR1SLC6A2MAOA | |
| SCHEMBL7196495 | 0.98 | CYP3A4 (0.33) | CYP3A4TDP1TAAR1SLC6A2MAOA | |
| SCHEMBL828451 | 0.98 | CYP3A4 (0.33) | CYP3A4TDP1TAAR1SLC6A2MAOA | |
| SCHEMBL5177211 | 0.98 | CYP3A4 (0.33) | CYP3A4TDP1TAAR1SLC6A2MAOA | |
| Hydrochloric Acid SCHEMBL4527827 | 0.96 | CYP3A4 (0.32) | CYP3A4TDP1TAAR1 | |
| Hydrochloric Acid SCHEMBL7834687 | 0.96 | CYP3A4 (0.32) | CYP3A4TDP1 | |
| Hydrochloric Acid SCHEMBL9740749 | 0.96 | CYP3A4 (0.32) | CYP3A4TDP1TAAR1 | |
| Hydrochloric Acid SCHEMBL4527828 | 0.96 | CYP3A4 (0.32) | CYP3A4TDP1 | |
| Hydrochloric Acid SCHEMBL10627872 | 0.96 | CYP3A4 (0.32) | CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 527 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6136746-A | USEFUL IN HYDROGENATION OF SUBSTITUTED ALPHA,BETA-UNSATURATED ACIDS AND ESTERS | SETON HALL UNIVERSITY (US) | 2000-10-24 | — | — | US | claimed |
| US-6025295-A | CATALYST COMPRISING SUPPORT, HETEROPOLY ACID ANCHORING AGENT, METAL COMPLEX; HYDROGENATION CATALYSTS | SETON HALL UNIVERSITY (US) | 2000-02-15 | — | — | US | claimed |
| US-6005148-A | COMPRISING SUPPORT, ANCHORING AGENT SUCH AS HETEROPOLY ACID OR ANION, AND METAL COMPLEX USEFUL IN HYDROGENATION OF SUBSTITUTED UNSATURATED ACIDS AND ESTERS | SETON HALL UNIVERSITY (US) | 1999-12-21 | — | — | US | claimed |
| US-4912221-A | Chiral 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid and precursors and preparation thereof | OCCIDENTAL CHEMICAL CORPORATION (US) | 1990-03-27 | — | — | US | claimed |
| CN-112189010-B | Triazole N-linked carbamoyl cyclohexyl acid as LPA antagonists | 百时美施贵宝公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260109676-A1 | HETEROCYCLIC COMPOUNDS AND RELATED METHODS | RECURSION PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-3986553-B1 | CYCLOBUTYL CARBOXYLIC ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4709710-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3728210-B1 | ISOXAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12528779-B2 | Heterocyclic compounds and related methods | RECURSION PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3710422-B1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY AND DIASTEREOMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES | SYNGENTA CROP PROTECTION AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| EP-3728209-B1 | CYCLOHEXYL ACID ISOXAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-1983003828-A1 | 1-CARBOXYALKANOYLPERHYDROINDOLE-2-CARBOXYLIC ACIDS AND DERIVATIVES | CIBA-GEIGY AG (CH) | 1983-11-10 | — | — | WO | disclosed |
| US-4393240-A | BIS(DIPHENYPHOSPHINO) PROPANE DERIVATIVES FOR MAKING RHODIUM COMPLEX CATALYSTS | STILLE JOHN K | 1983-07-12 | — | — | US | disclosed |
| US-4390700-A | HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS | CIBA-GEIGY CORPORATION (US) | 1983-06-28 | — | — | US | disclosed |
| US-4374847-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1983-02-22 | — | — | US | disclosed |
| US-4374062-A | ASSYMETRICAL HYDROGENATION OF DEHYDROPEPTIDES USING A PHODIUM COMPLEX CATALYST | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1983-02-15 | — | — | US | disclosed |
| EP-0051301-A1 | 1-Carboxy-azaalkyl-indolin-2-carboxylic acids, process for preparing them, pharmaceutical compositions containing them and their therapeutical use | CIBA-GEIGY AG (CH) | 1982-05-12 | — | — | EP | disclosed |
| EP-0050850-A1 | 1-Carboxyalkanoylindolin-2-carboxylic acids and derivatives thereof, processes for their preparation, and pharmaceutical compositions containing these compounds | CIBA-GEIGY AG (CH) | 1982-05-05 | — | — | EP | disclosed |
| EP-0050196-A1 | Process for the preparation of peptides | Degussa Aktiengesellschaft (DE) | 1982-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109676-A1 | HETEROCYCLIC COMPOUNDS AND RELATED METHODS | SLC10A1, SCN1B, HSD3B2 | CYP3A4 309/4885TDP1 1114/4885TAAR1 343/4885 |
| US-12528779-B2 | Heterocyclic compounds and related methods | SLC10A1, SCN1B, NPY5R | CYP3A4 268/4885TDP1 1644/4885TAAR1 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.